Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.indswift.com | |
Market Cap | 54.44 Cr. | |
Enterprise Value(EV) | 1,031.90 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -5.91 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | -131.03 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | -0.08 | Calculated using Price: 10.05 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 5.42 Cr. | 54,164,653 Shares |
FaceValue | 2 | |
Company Profile | ||
Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company. Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore. Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network. Business areas of the company are: Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty. Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.
Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies. Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases. Awards/ Achievements
|
1 Day |
|
|
1 Week |
|
+6.12% |
1 Month |
|
-16.39% |
3 Month |
|
-20.36% |
6 Month |
|
-14.76% |
1 Year |
|
+83.39% |
2 Year |
|
+390.24% |
5 Year |
|
+30.69% |
10 Year |
|
-59.56% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | -55.75 | -112.51 | ||||||||
Return on Capital Employed (%) | -3.10 | -4.27 | -10.41 | -20.35 | -56.22 | -10.31 | 3.37 | 5.82 | 7.19 | |
Return on Assets (%) | -7.48 | -8.26 | -11.09 | -17.47 | -42.12 | -8.45 | 1.35 | -3.19 | -4.68 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 217 | 108 | -40 | -239 | -611 | -679 | -677 | -713 | -695 | -704 | |
Non Curr. Liab. | 609 | 596 | 549 | 679 | 672 | 694 | 659 | 661 | 661 | 645 | |
Curr. Liab. | 581 | 686 | 718 | 621 | 608 | 598 | 616 | 654 | 706 | 708 | |
Minority Int. | |||||||||||
Equity & Liab. | 1,407 | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 649 | |
Non Curr. Assets | 519 | 506 | 469 | 439 | 463 | 427 | 405 | 373 | 406 | 397 | |
Curr. Assets | 843 | 851 | 738 | 612 | 206 | 186 | 194 | 229 | 265 | 252 | |
Misc. Exp. not W/O | 45 | 33 | 21 | 10 | |||||||
Total Assets | 1,407 | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 649 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 393 | 570 | 417 | 304 | 263 | 270 | 289 | 330 | 356 | 386 | |
Other Income | 6 | 13 | 2 | 13 | 14 | 15 | 8 | 22 | 15 | 17 | |
Total Income | 399 | 583 | 419 | 317 | 277 | 284 | 297 | 352 | 371 | 403 | |
Total Expenditure | -416 | -604 | -487 | -461 | -328 | -264 | -278 | -306 | -315 | -351 | |
PBIDT | -16 | -21 | -68 | -144 | -52 | 21 | 19 | 46 | 57 | 52 | |
Interest | -86 | -77 | -40 | -19 | -16 | -11 | -4 | -35 | -52 | -51 | |
Depreciation | -18 | -26 | -39 | -36 | -36 | -35 | -34 | -34 | -33 | -32 | |
Taxation | 10 | 9 | 2 | 0 | -1 | -1 | -2 | 0 | -1 | ||
Exceptional Items | -260 | -28 | 27 | 6 | -1 | 0 | |||||
PAT | -111 | -116 | -145 | -200 | -364 | -54 | 8 | -19 | -30 | -32 | |
Adjusted EPS | -24 | -23 | -29 | -40 | -67 | -10 | 2 | -4 | -6 | -6 |
Particulars | 10 years | 2012-06 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 94 | -146 | 103 | 86 | -106 | 7 | 1 | 43 | 35 | 77 | |
Cash Fr. Inv. | -184 | -28 | -14 | -6 | -4 | -4 | -3 | -14 | -11 | -17 | |
Cash Fr. Finan. | 99 | 146 | -89 | -81 | 110 | -11 | -4 | -13 | -26 | -48 | |
Net Change | 9 | -28 | 0 | -1 | 0 | -8 | -5 | 16 | -3 | 12 | |
Cash & Cash Eqvt | 46 | 18 | 18 | 17 | 17 | 9 | 4 | 20 | 17 | 29 |
Mon, 16 May 2022
Board Meeting Intimation for Consideration Of Inter-Alia The Standalone Audited Financial Results For Q4 And Financial Year Ended 31St March 2022. IND-SWIFT LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve And take on record the Standalone Audited Financial Results of the Company for the Fourth Quarter (Q4) and Financial Year ended March 31 2022. |
|||||||||||||||||||||
Sat, 14 May 2022
Announcement under Regulation 30 (LODR)-Acquisition Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the company has registered a wholly owned subsidiary (WOS) in Republic of Kenya under the name of INDSWIFT INDIA LIMITED on 13th May 2022. The disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9 2015 is enclosed as Annexure - I to this intimation. |
|||||||||||||||||||||
Sat, 30 Apr 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: company in process of appointment of CS Designation: . EmailId: companysec@indswift.com Name of the Chief Financial Officer: Arun Seth Designation: General Manager Accounts and Finance EmailId: arunseth@indswift.com Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
Wed, 18 May 2022 |
|
|
|
|
|